Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levocabastine QD vs BID in Allergic Rhinitis
NCT01949051Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2013
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of levocabastine in allergic rhinitis (AR) (3 arms), sponsored by GSK. Primary endpoint: Total Nasal Symptom Score at Day 8. Started Oct 2013; status: completed.
02
Drugs
levocabastine
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT01949051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01949051.